Summary of Study ST000491

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000370. The data can be accessed directly via it's Project DOI: 10.21228/M87604 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST000491
Study Title	Sleep apnea and cardiovascular samples amino acid metabolites
Study Summary	Sleep apnea and cardiovascular samples amino acid metabolites
Institute	Mayo Clinic
Laboratory	Mayo Clinic Metabolomics Resource Core
Last Name	Pak
First Name	Victoria
Address	unknown
Email	victoria.pak@yale.edu
Phone	203-737-5065
Submit Date	2016-10-14
Analysis Type Detail	LC-MS
Release Date	2018-10-10
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR000526
Treatment Summary:	Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Treatment ID:

TR000526

Treatment Summary:

Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.